Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05288166 · ClinicalTrials.gov registry record · Phase 3
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
A Phase 3 study of Prostatic Neoplasms and Neoplasm Metastasis, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 925
- Enrollment target
- 20
- Study locations
NCT05288166 is a Phase 3 study of Prostatic Neoplasms and Neoplasm Metastasis that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 925 participants, above the 500-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (85% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT05288166, a Phase 3 study of Prostatic Neoplasms and Neoplasm Metastasis, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 925 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
Conditions Studied
Interventions
- DRUG Abemaciclib
- DRUG Abiraterone
- DRUG Prednisone or Prednisolone
- DRUG Placebo for Abemaciclib
Study Locations (20)
California
- Orange Coast Memorial Medical Center - Fountain Valley
- Providence Medical Foundation - Fullerton
- Moores Cancer Center - La Jolla
- MemorialCare Health System - Long Beach Medical Center - Long Beach
- Cancer and Blood Specialty Clinic - Los Alamitos
- UCLA Hematology/Oncology - Santa Monica - Los Angeles
- Torrance Memorial Physician Network / Cancer Care - Torrance
- PIH Health Hematology Medical Oncology - Whittier
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
- UCHealth Memorial Hospital - Colorado Springs
- UCHealth Harmony - Fort Collins
- Colorado West Healthcare System - Grand Valley Oncology - Grand Junction
- USO-Rocky Mountain Cancer Center - Littleton
Arizona
- Arizona Oncology Associates, P.C. - HOPE - Prescott
- Arizona Oncology Associates, P.C. - HOPE - Prescott Valley
- The University of Arizona Cancer Center - North Campus - Tucson
Arkansas
- Genesis Cancer and Blood Institute - Hot Springs
- St. Bernards Medical Center - Jonesboro
- Highlands Oncology Group - Springdale
Florida
- Florida Cancer Specialists - South - Fort Myers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 925 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2027-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05288166
The ClinicalTrials.gov registry entry for NCT05288166 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 925 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 500-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (85% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Prostatic Neoplasms appearing as the primary indexed condition, and to 4 interventions - of which Abemaciclib is the first listed.
NCT05288166 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Arizona.
Frequently Asked Questions
What is clinical trial NCT05288166 about?
NCT05288166 is a clinical study titled "A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)". The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
What is the current status of trial NCT05288166?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 925 participants. The study started on 2022-04-14. Estimated completion is 2027-10.
What conditions does trial NCT05288166 study?
This clinical trial studies the following conditions: Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Hormones.
What interventions are being tested in trial NCT05288166?
The interventions under investigation include: Abemaciclib (DRUG), Abiraterone (DRUG), Prednisone or Prednisolone (DRUG), Placebo for Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT05288166?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05288166 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
RECRUITING · Phase 3
-
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
RECRUITING · Phase 3
-
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
RECRUITING · Phase 3
-
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
ACTIVE NOT RECRUITING · Phase 3
-
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.